0NES
+0.0 · +0.00%
EUR · LSE

Oriola Oyj Series B(0NES) Stock Analysis

EUR --+0.00%
Reward42Moderate
Risk35Moderate
75%Data
Thin -1% profit margin · 3.3% dividend yield
Value Trap
Market Cap:170.91M
ⓘ
Reward Rating
42
Moderate
Reward Assessment
75% data coverage
Bottom 10% of stocksView factors
ⓘ
Risk Rating
35
Moderate
Risk Assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0NES to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Oriola Oyj Series B?

Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally.

AI Brief Pro

The brief on Oriola Oyj Series B

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Oriola Oyj Series B?

Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. The company is listed on the LSE in UK, with a market capitalisation of 170.91M, and a P/E ratio of 0.1x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (42)
Company Information
SectorN/A
IndustryN/A
Market Cap170.91M
P/E Ratio0.0769
Beta0.48
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.